Cannabis Rescheduling Won't Save Crashed Marijuana Stocks

Cannabis stocks continue trading near multi-year lows despite growing optimism around federal marijuana rescheduling, with major operators like Tilray Brands (TLRY) down over 90% from peak valuations. The disconnect between regulatory progress and stock performance highlights deeper structural issues plaguing the sector that rescheduling alone cannot resolve.

The Biden administration's push to move marijuana from Schedule I to Schedule III represents the most significant federal cannabis policy shift in decades, potentially reducing the 280E tax burden that has crushed operator margins. However, this regulatory win fails to address core problems including oversupply, price compression, and limited interstate commerce that have decimated company valuations across the board.

Canadian licensed producers face additional headwinds as domestic market saturation intensifies competition while U.S. market access remains restricted. Tilray's diversification into alcohol and international markets provides some insulation, but the company's core cannabis operations still grapple with declining flower prices and margin pressure that rescheduling cannot immediately fix.

U.S. multi-state operators trading on Canadian exchanges have similarly struggled despite stronger fundamentals, as institutional investment remains limited and capital access constrained. Companies like Curaleaf (CURA) and Green Thumb Industries (GTII) trade at steep discounts to traditional retail comparables, reflecting ongoing federal prohibition concerns among mainstream investors.

While rescheduling could catalyze some recovery by improving banking access and reducing compliance costs, the path to sustained stock price appreciation requires operational execution and market consolidation. Investors betting on regulatory catalysts alone may face continued disappointment as oversupplied markets and competitive dynamics keep pressure on cannabis equities regardless of federal scheduling changes.